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Background: In Tanzania, 5.1% of adults aged 15-49 are infected with HIV. While rates of HIV-related malignancies
have declined globally with antiretroviral therapy (ART), including Tanzania, rates of non-AIDS-defining cancers
(NADCs) are believed to have increased. Therefore, we determined trends of three NADCs in Tanzania: ano-rectal
cancer, squamous cell carcinoma of the eye, and Hodgkin’s lymphoma.
Methods: This study was conducted at the Ocean Road Cancer Institute (ORCI) in Dar es Salaam. All medical
records of patients diagnosed with ano-rectal cancer, squamous cell carcinoma of the eye, and Hodgkin’s lymph-
oma between 2002 and 2012 were reviewed regarding HIV status, cancer clinical characteristics and management.
Analysis was conducted to determine trends and proportions in these three NADCs and patient characteristics.
Results: We identified 980 NADCs. The relative proportion of these three NADCs at ORCI out of all cancers treated
increased from 2.37% in 2002 to a peak of 4.34% in 2009. The prevalence of HIV in patients diagnosed with these
NADCs also increased—from 6.67% in 2002 to 20.87% in 2010—and 85% of squamous cell carcinoma of the eye
cancer patients with a reported HIV status were HIV-positive.
Conclusions: The frequency and proportions of these three NADCs in Tanzania have increased over the past 11
years, as has the prevalence of HIV positivity amongst these NADC patients. The current and possibly increasing
burden of NADCs in Tanzania and other low- and middle-income countries with high HIV rates should be a focus
for future cancer prevention and control and HIV therapy programs.
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InstituteBackground
The occurrence of 14.1 million incident cancer cases
and 8.2 million cancer deaths in 2012 indicates that can-
cer is a major public health problem rising worldwide,
especially in developing countries [1]. Tanzania, for in-
stance, had 33,884 new cancer cases and 23,648 cancer
deaths in 2012 [1].* Correspondence: amr.soliman@unmc.edu
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unless otherwise stated.Infection-associated cancers comprise a greater pro-
portion of the cancer burden in developing regions com-
pared to high-income regions, with 32.7% of cancers in
sub-Saharan Africa attributable to infections [2,3]. Of
primary concern, especially in sub-Saharan Africa, are
malignancies associated with HIV, as the majority of the
35.3 million people around the world living with HIV
reside in low- and middle-income countries [4]. In 2012
alone, 2.3 million people were newly infected with HIV
and 1.6 million people died of HIV/AIDS [4]. In
Tanzania, 5.1% of adults aged 15-49 are infected withl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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control both HIV infection and related malignancies [5].
Antiretroviral therapy (ART) has helped restore immune
system function to a large extent in patients and has
prolonged survival of individuals with HIV [6]. Though
the incidence of AIDS-defining cancers (meaning an in-
dividual is defined as having AIDS if he or she presents
with Kaposi’s sarcoma, non-Hodgkin’s lymphoma, or in-
vasive cervical cancer) showed significant increases in
incidence corresponding to the evolution of the HIV/
AIDS epidemic, with striking increases in Kaposi’s sar-
coma observed particularly in Africa [7], treatment has
resulted in a decrease of these three cancers in devel-
oped regions of the world [6,8]. We have also docu-
mented the declining trend in Kaposi’s sarcoma in
Tanzania over the past ten years [9]. However, the num-
ber of non-AIDS defining cancers (NADCs)—cancers
other than those three—has significantly increased, pos-
sibly due to multiple risk factors associated with the
chronically treated HIV population, such as increased
longevity and milder forms of immune deficiency that
may persist even with antiretroviral therapy [6,8,10].
With increasing access to ART, survival of HIV-
positive individuals has increased, resulting in a rise of
the NADC burden throughout the world [11]. HIV-
positive individuals are at a higher risk for many other
cancers, including anal, liver, prostate, lung and Hodg-
kin’s lymphoma, though evidence for increased risks of
NADCs throughout Africa is not consistent [11,12]. The
HIV population in sub-Saharan Africa is also thought to
be at increased risk for squamous cell carcinoma of the
conjunctiva, suggesting potentially differing patterns and
burden of NADCs between Africa and other parts of the
world, due to multifactorial exposures, co-morbid condi-
tions, and hereditary factors [11]. Although two-thirds of
the HIV epidemic burden is concentrated in sub-
Saharan Africa, little is known about the pattern of
NADCs in the region; this is due, at least in part, to
under-diagnosis of cancer and sparse cancer registration,
as well as limited HIV status data of incident cancers
[7,8,13,14]. With such a large HIV burden in sub-
Saharan Africa, current efforts must focus on mitigating
the burden of cancer in the region.
With the introduction of ART to Tanzania in 2004, it
is important to examine the effect of improved immune
response and prolonged survival of HIV patients on
NADC trends. Describing the time period just before
widespread ART access and during the ART era is im-
portant because studies show increasing NADC rates
shortly after ART is introduced into a population
[15,16]. Therefore, we conducted this study to determine
trends of three specific and highly treatable (in high re-
source environments) NADCs frequently treated in
Tanzania: ano-rectal cancer, squamous cell carcinoma ofthe eye, and Hodgkin’s lymphoma during the period of
2002-2012.Results
Records from 980 cases of ano-rectal, squamous cell car-
cinoma of the eye, and Hodgkin’s lymphoma were ab-
stracted. The absolute number of cases tripled during
the 11-year period for these three NADCs, while the
Tanzanian population increased by only 25% [17]. The
relative proportion of cancer diagnosed at ORCI as one
of these three NADCs increased from 2.37% in 2002 to a
peak of 4.34% in 2009 (Joinpoint logarithmic annual per-
cent change (APC) = 4.68%) (Figure 1). The prevalence
of HIV in patients diagnosed with these three NADCs
also increased—from 6.67% in 2002 to 20.87% in 2010
(APC = 16.02%) (Figure 2). Of the known HIV positive
patients, 75% were patients diagnosed with squamous
cell carcinoma of the eye; 18% had ano-rectal cancer;
and 7% had Hodgkin’s lymphoma. The gender distribu-
tion for patients with squamous cell carcinoma of the
eye and ano-rectal cancer were roughly equal, whereas
there was approximately double the number of male
Hodgkin’s lymphoma patients compared to females, con-
sistent with population-level data from East African
countries reported in Cancer Incidence in Five Conti-
nents [18]. Approximately 30% of males and females had
a known HIV status recorded in their medical record,
with 19.2% of all females being HIV-positive and 11.2%
of all males being HIV-positive, representing a female to
male ratio of 1.7, similar to the known ratio of 1.6 be-
tween HIV-positive females and males in the general
Tanzania population [5].
Unconditional logistic regression models were used to
assess the characteristics of different groups of the NADC
patients at ORCI. Compared to HIV negative patients,
HIV positive patients were more likely to be older (Odds
ratio (OR) = 1.02, 95% CI: 1.01-1.04); female (OR = 1.78,
95% CI: 1.12-2.82); have advanced cancer stage (OR = 5.82,
95% CI: 1.24-27.29); have received radiotherapy (OR = 3.5,
95% CI: 2.10-5.7); have not received chemotherapy (OR =
0.21, 95% CI: 0.13-0.34); and have fewer co-morbidities
(OR = 0.52, 95% CI: 0.41-0.67) (Table 1). Though not statis-
tically significant, HIV-positive patients were more likely to
reside in Dar es Salaam (OR = 1.57, 95% CI: 0.98-2.54) and
have tuberculosis (OR = 2.54, 95% CI: 0.95-6.81). When
stratified by year, a more than two-fold increase in HIV-
positive NADC cases occurred in 2008, with most of the
increase resulting from a rise in the number of HIV-
positive squamous cell carcinoma of the eye cases. The
population of newly diagnosed NADC cases with HIV also
became older overall over the 11-year period, increasing
from an average of 27 years old in 2002 (median = 36) to
42 years old in 2012 (median = 40).
Figure 1 Joinpoint regression analysis describing the annual percent change (APC) in ano-rectal cancer, squamous cell carcinoma of
the eye, and Hodgkin’s lymphoma cases over time in all cancer patients presenting to Ocean Road Cancer Institute, 2002-2012 (^ indicates
significance at the 95% confidence level).
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with a known HIV status and patients with no recorded
HIV status in their medical records, these two groups were
compared. Patients with a known HIV status were more
likely to be female (OR = 1.42, 95% CI: 1.08-1.87); received
radiotherapy (OR = 1.42, 95% CI: 1.06-1.90); have more
co-morbidities (OR = 1.34, 95% CI: 1.19-1.51); and have
tuberculosis (OR = 8.11, 95% CI: 3.22-20.40), compared to
patients with no recorded HIV status (Table 2).
Patient characteristics of the three studied NADCs are
documented in Table 3 to describe differences in these
groups of patients. Ano-rectal cancer patients had the
oldest age at diagnosis and Hodgkin’s lymphoma pa-
tients had the youngest; Hodgkin’s lymphoma patientsFigure 2 Joinpoint regression analysis describing the annual percent
carcinoma of the eye, and Hodgkin’s lymphoma cases over time in pa
these three NADCs, 2002-2012 (^ indicates statistical significance at twere also more likely to be male; squamous cell carcinoma
of the eye patients were most likely to have a reported and
positive HIV status; and Hodgkin’s lymphoma patients
tended to have more co-morbidities (Table 3).
Discussion
This study is the first study from the only cancer center
in Tanzania that addresses the burden and proportional
changes in distributions of three common non-AIDS-
defining cancers before and after the introduction of
ART into the country. The study reveals the following
interesting observations: First, the frequency of the three
NADCs studied has increased over the past 11 years at
ORCI, as has the prevalence of HIV positivity in thesechange (APC) in HIV positive ano-rectal cancer, squamous cell
tients presenting to Ocean Road Cancer Institute with one of
he 95% confidence level).
Table 1 Characteristics of NADC patients at Ocean Road Cancer Institute, 2002-2012, by HIV statusa
HIV positive (N = 147) HIV negative (N = 151)
N (%)b N(%) P valuec OR (95% CI)d
Age (years)
Mean ± SD 40.6 ± 10.1 35.0 ± 19.1 0.0024* 1.02 (1.01, 1.04)
Female 90 (61.2%) 71 (47.0%) 0.0142* 1.78 (1.12, 2.82)
Dar es Salaam residence 60 (40.8%) 46 (30.5%) 0.0627 1.57 (0.98, 2.54)
Advanced cancer stage (% of reported) 43 (95.6%) 48 (78.7%) 0.0254* 5.82 (1.24, 27.29)
Cancer treatment
Radiotherapy 110 (75.3%) 68 (46.9%) <.0001* 3.5 (2.10, 5.70)
Chemotherapy 51 (35.2%) 105 (72.4%) <.0001* 0.21 (0.13, 0.34)
Both 40 (27.6%) 41 (28.3%) 0.8959 0.97 (0.58, 1.61)
Co-morbidities
Mean ± SD (count) 0.61 ± 0.86 1.43 ± 1.43 <.0001* 0.52 (0.41, 0.67)
Tuberculosis 14 (9.5%) 6 (4.0%) 0.0633 2.54 (0.95, 6.81)
Died 16 (11.4%) 18 (12.5%) 0.7641 0.90 (0.44, 1.84)
aHIV status missing/unknown = 682.
bTotals vary due to missing data.
cChi-squared tests/Fisher’s exact test for categorical variables and t-test/Wilcoxon rank-sum tests for continuous variables.
dOdds ratio (95% CI) calculated from unconditional logistic regression model.
*Significant at alpha < .05.
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lem in Tanzania. Second, a clear link was observed be-
tween HIV and squamous cell carcinoma of the eye.
Third, this study reveals a distinct treatment pattern of
NADC patients based upon HIV serostatus.
The association between HIV infection and a wide range
of cancers has been thoroughly documented in Western
countries, particularly for the three AIDS-defining cancersTable 2 Characteristics of NADC patients at Ocean Road Canc
2002-2012
HIV known (N = 298
N (%)a
Age (years)
Mean ± SD 37.8 ± 15.5
Female 161 (54.0%)
Dar es Salaam residence 106 (35.6%)






Mean ± SD (count) 1.02 ± 1.25
Tuberculosis 20 (6.7%)
Died 34 (11.9%)
aTotals vary due to missing data.
bChi-squared tests/Fisher’s exact test for categorical variables and t-test/Wilcoxon ra
cOdds ratio (95% CI) calculated from unconditional logistic regression model.
*Significant at alpha < .05.(ADCs)—Kaposi’s sarcoma, non-Hodgkin’s lymphoma and
cervical cancer [19-22]. Recent studies have shown the de-
clining trend in ADCs around the world with improved
immune function of patients in the antiretroviral era
[9,13,19,21,23,24]. However, with the dropping rates of
ADCs, the frequency of many other cancers—NADCs—
have begun rising, primarily documented in developed re-
gions, with no clear evidence of why incidence is increasinger Institute according to recorded status of HIV,
) HIV missing (N = 682)
N(%) P valueb OR (95% CI)c
40.4 ± 22.0 0.0609 0.99 (0.99, 1.00)
308 (45.2%) 0.0114* 1.42 (1.08, 1.87)
243 (35.6%) 0.9856 1.0 (0.75, 1.33)
140 (78.2%) 0.1145 1.69 (0.88, 3.24)
284 (52.6%) 0.0178* 1.42 (1.06, 1.90)
296 (54.7%) 0.7995 0.96 (0.72, 1.28)
137 (25.4%) 0.4243 1.14 (0.83, 1.57)
0.65 ± 1.02 <.0001* 1.34 (1.19, 1.51)
6 (0.9%) <.0001* 8.11 (3.22, 20.40)
54 (10.1%) 0.4138 1.21 (0.77, 1.91)
nk-sum tests for continuous variables, depending on the normality of the data.
Table 3 Characteristics of patients at Ocean Road Cancer Institute, 2002-2012, by non-AIDS-defining cancera
Ano-rectal
(N = 395)




N (%) N (%) N (%)
Age (years)
Mean ± SD 51.0 ± 16. 8 38.3 ± 18.2 25.2 ± 17.0
Female 209 (52.9%) 166 (55.0%) 94 (33.3%)
Dar es Salaam residence 162 (41.0%) 100 (33.1%) 87 (30.7%)
HIV reported 81 (20.5%) 129 (42.7%) 88 (31.1%)
HIV positive (% of HIV reported) 27 (33.3%) 110 (85.3%) 10 (11.4%)
Advanced stageb (% of reported stage) 122 (94.6%) 61 (100%) 48 (50.5%)
Cancer treatment
Radiotherapy 229 (63.6%) 185 (74.6%) 48 (21.5%)
Chemotherapy 224 (62.2%) 39 (15.8%) 189 (84.4%)
Both 148 (41.1%) 34 (13.8%) 36 (16.1%)
Co-morbidities
Mean ± SD 0.72 ± 0.99 0.23 ± 0.51 1.39 ± 1.39
Tuberculosis 3 (0.8%) 14 (4.6%) 9 (3.2%)
Died 49 (13.8%) 17 (6.9%) 22 (10.1%)
aTotals vary due to missing data.
bStage III, IV, or unspecified advanced stage.
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have no known relation to viral oncogenes and are not as-
sociated with degree of immunodeficiency [13]. For in-
stance, CD4 count was not predictive of NADCs in a study
conducted in HIV-infected individuals receiving care at a
military HIV clinic in the United States [25]. In contrast, a
recent study from the Brussels St-Pierre urban cohort in
Belgium, of which sub-Saharan Africans migrants repre-
sented 47% of the study population, reported low CD4
count as predictive of NADCs [26]. Though evidence re-
mains unclear and contradictory across populations re-
garding the association between HIV and certain cancers
[13,20,24,26], studies do show significantly increased rates
of NADCs since the widespread use of antiretrovirals
[15,16]. In the United States, the rates of Hodgkin’s lymph-
oma as well as skin, anal, lung, kidney and liver cancers are
higher in HIV-infected cohorts compared to the general
population [6,25,27]. In Belgium, with nearly half the study
population of sub-Saharan African origin, Hodgkin’s
lymphoma and cancers of the anal, bladder and liver were
increased in incidence in HIV patients [26]. In sub-Saharan
Africa, studies have shown positive associations between
HIV and squamous cell conjunctival carcinoma of the eye,
Hodgkin’s lymphoma, and cancers of the lung, liver, anus,
penis, vulva, kidney, thyroid and uterus [11,23]. It is clear
that many cancers are becoming a greater burden through-
out the world in HIV-infected persons since the wide-
spread use of antiretrovirals.
The strong link between HIV and squamous cell carcin-
oma of the eye in this study is supported by other studiesin sub-Saharan Africa in which HIV patients showed an
increased risk for squamous cell carcinoma of the con-
junctiva (SCCC), calling into question whether this cancer
should be considered AIDS-defining, particularly in sub-
Saharan Africa where ultraviolet (UV) light exposure is
greater than other parts of the world [28]. Though the eti-
ology of SCCC remains largely unclear, UV radiation has
been implicated in carcinoma development [29]. For in-
stance, a case-control study in Uganda and Malawi found
a significant association between HIV and conjunctival
carcinoma, showing the interactions between both ultra-
violet light and HPV, among other factors, likely contrib-
ute to the pathogenesis of carcinoma [28]. Further, the
Uganda AIDS-Cancer Registry Match Study found cancers
of the conjunctiva to have a standardized incidence ratio
(SIR) of 4.0 in the HIV population compared to persons
not infected with HIV [11]. UV radiation and HPV are
also strongly associated with increased SCCC risk among
persons with HIV in the United States [30,31]. Given the
unclear nature of SCCC pathogenesis and the rise in inci-
dence over the past decade, urgent research is needed glo-
bally into the pathogenic events leading to this cancer in
long-standing HIV-positive individuals [11,28]. Considering
squamous cell carcinoma of the eye as an AIDS-defining
malignancy could bring about not only policy changes but
also a greater opportunity for cancer prevention and early
detection of HIV-related malignancies. For instance, physi-
cians may be more likely to test these patients for HIV if
knowledge about the association increases, thus allowing
for more comprehensive and effective ascertainment and
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squamous cell carcinoma of the eye and HIV.
Finally, the characterization of patients indicates that
the utilization of resources between different populations
of NADC patients differs, providing important data for
the improvement of treatment for cancer patients with
HIV in Tanzania. For instance, HIV-positive patients
were more likely than HIV-negative patients to undergo
radiation therapy, while HIV-negative patients were
more likely to receive chemotherapy. It is possible that
this difference is due to a reluctance to utilize chemo-
therapy in patients who are on retroviral treatment for
fear of drug interactions and/or of undermining HIV
control, suggesting that research is needed to understand
whether specific guidelines need to be developed for the
cancer treatment of long-term HIV carriers. Some re-
search currently exists suggesting the potential benefits
of chemoradiation in HIV-positive patients with cancer.
For instance, HIV-infected individuals in the UK with
anal carcinoma showed a high complete response rate
after radical chemoradiation [32]. It is also important to
develop specific treatment regimens based on the pa-
tient’s CD4 count, since patients with a count less than
200 are more likely to suffer therapy-related toxicity
from chemoradiation [33].
Given the current scarcity of epidemiologic research in
Tanzania and sub-Saharan Africa in general, this study has
a number of strengths. This study of NADCs builds upon
previous work analyzing trends in the AIDS-defining can-
cer, Kaposi’s sarcoma, providing a clearer picture of the ef-
fect of HIV in Tanzania [9]. Trends of these NADCs have
never been documented in Tanzania—and are limited in
sub-Saharan Africa in general—so this study provides a
crucial first step in understanding the burden of cancer in
HIV-infected individuals in the country and the region as
antiretroviral use becomes more widespread. Though this
study only describes three cancers, it creates knowledge
for future research into these cancers and other NADCs.
Further, though Tanzania lacks a population-based cancer
registry, this study shows that the burden of disease can
be reasonably assessed from the hospital-based registry at
ORCI. For instance, the expected female to male ratio of
cancer incidence from Cancer Incidence in Five Continents
and HIV prevalence from Tanzania’s HIV/AIDS and Mal-
aria Indicator Survey are congruent with the observed
data from ORCI medical records [5,18].
As only three NADCs were examined due to data con-
straints, this study is limited in generalizing to the trends
for all NADCs in Tanzania. Future studies should include
a wider range of cancers if possible, including hepatocellu-
lar carcinoma and head and neck cancers. Further, we can-
not determine the extent to which the increasing trends
for these NADCs is a reflection of the HIV population liv-
ing longer on ART or simply an increasing proportion ofthese three cancers being referred to ORCI for treatment
compared to other cancers. Since this was a secondary
analysis utilizing patient medical records, the study was
limited by the completeness of the records. For instance,
no routine screening of HIV exists at ORCI, resulting in
significant missing information on HIV status. As such,
the observed trends in rising trends of HIV-positive pa-
tients with one of the three reported NADCs should be
considered with caution. Similarly, cancer risk factors,
such as HPV exposure or carrier status, are not readily re-
corded in a patient’s record, particularly for the three
NADCs studied. Anogenital and conjunctival cancers are
HPV-related tumors; thus, the increase in these cancers
could potentially be due to the increase in HPV prevalence
of certain serotypes [28,31]. More research will need to be
conducted to settle the molecular and possibly infectious
basis of these cancers in the HIV population.
Given these limitations, a recommendation for Tanzania
is to promote the creation of a centralized National AIDS
Control Program (NACP) database system. The existing
system hinders the ability to create linkages between can-
cer registries and HIV registries in Tanzania. A centralized
system in which all HIV registries throughout the country
are available in one database is crucial to determine the
risk of specific cancers for HIV-infected individuals in
Tanzania by conducting cancer-HIV linkage studies, simi-
lar to the studies recently conducted in Uganda and
Nigeria [11,12]. In addition, improving the data quality
and comprehensiveness of medical records to include HIV
status and HIV duration is needed to better assess the
spectrum of cancers in the HIV population in Tanzania.
Conclusions
In summary, this research, for the first time, brings aware-
ness about the possible increasing burden of non-AIDS-
defining cancers in Tanzania. In particular, this study
quantifies the link between squamous cell carcinoma of
the eye and HIV in Tanzania, as observed in other coun-
tries of sub-Saharan Africa [11,34]. Whether or not this
cancer should be considered as an AIDS-defining-cancer,
it is clear that a better understanding of the etiology of
squamous cell carcinoma of the eye and other cancers
with HIV in sub-Saharan Africa is needed. More compre-
hensive studies can be conducted at ORCI to assess rea-
sons for increases in prevalence of all three of the studied
cancers as well as other non-AIDS-defining cancers (e.g.,
hepatocellular carcinoma and head and neck cancers) by
conducting more in-depth studies that include interview-
ing patients for detailed information on risk factors, such
as smoking status and HPV infection. Further, growth in
education programs aimed at disseminating information
to foster early detection is essential, as early treatments
are generally effective in malignancies such as squamous
cell carcinoma of the eye. Early detection is particularly
Meernik et al. Infectious Agents and Cancer 2014, 9:42 Page 7 of 8
http://www.infectagentscancer.com/content/9/1/42relevant in the HIV population because HIV-infected can-
cer patients experience an increased risk of death follow-
ing cancer diagnosis compared to cancer patients not
infected with HIV [34]. Ultimately, the increase in preva-
lence of NADCs has implications for further study and
may lead to the implementation of prevention and treat-
ment programs and cancer control policies.
Methods
The study was conducted at the Ocean Road Cancer In-
stitute (ORCI), the only cancer center in Tanzania where
the vast majority of cancer patients receive treatment.
ORCI is located in Dar es Salaam, the capital city of
Tanzania and receives cancer patients from all regions of
the country. Though Tanzania maintained a population-
based registry in the past, it is currently in the process of
being rebuilt after it disbanded in 2003/2004 [35]. The
hospital-based cancer registry maintained at ORCI was
utilized for this study.
Data collection
We identified, retrieved and abstracted medical records of
all 980 patients diagnosed/or treated at ORCI during the
period of 2002-2012 with clinically and/or histologically
confirmed ano-rectal cancer, squamous cell carcinoma of
the eye, or Hodgkin’s lymphoma. These three cancers
were selected to provide a general description of NADC
trends, as they are cancers frequently treated at ORCI and
for which the HIV population is at higher risk [8,10,11,13].
Cases were identified and patient records were abstracted
for the following variables: age, sex, religion, place of resi-
dence, place and date of pathological diagnosis, date of ad-
mission to ORCI, pathological characteristics, cancer type,
cancer grade and stage, cancer treatment protocol, HIV
status and treatment, co-morbidities such as pneumonia,
tuberculosis and anemia, and date of last known status of
the patient. The number of all cancers treated at ORCI
each year was obtained from record books and used as the
denominator for proportion calculations.
Data analysis
Trends in the proportion of NADC cases and the pro-
portion of HIV positivity in these cases were examined
using Joinpoint regression analysis (version 4.0.4). Join-
point analysis identifies significant changes in the slope
of the line of proportions over time and estimates the
annual percent change (APC) for each segment [36].
Univariate analysis assessed demographic and other
characteristics of NADC patients, stratified by year and
grouped for the 11-year period. Analysis was conducted
by HIV status (positive vs. negative status and known vs.
missing status). Categorical variables were examined with
Chi-squared tests or Kruskall-Wallis tests and continuous
variables were examined with t-tests or Wilcoxon rank-sum tests, depending on the normality of the data. Uncon-
ditional logistic regression models were used to calculate
odds ratios and 95% confidence intervals for the associa-
tions between HIV status and covariates of interest, in-
cluding age, gender, and number of co-morbidities. Data
was analyzed in SAS 9.3 (SAS Institute, Cary, NC).
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